JP2022500479A5 - - Google Patents
Info
- Publication number
- JP2022500479A5 JP2022500479A5 JP2021516638A JP2021516638A JP2022500479A5 JP 2022500479 A5 JP2022500479 A5 JP 2022500479A5 JP 2021516638 A JP2021516638 A JP 2021516638A JP 2021516638 A JP2021516638 A JP 2021516638A JP 2022500479 A5 JP2022500479 A5 JP 2022500479A5
- Authority
- JP
- Japan
- Prior art keywords
- sra141
- day
- cancer
- compound
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735778P | 2018-09-24 | 2018-09-24 | |
| US62/735,778 | 2018-09-24 | ||
| US201862760638P | 2018-11-13 | 2018-11-13 | |
| US62/760,638 | 2018-11-13 | ||
| PCT/US2019/019676 WO2019165473A1 (en) | 2018-02-26 | 2019-02-26 | Methods of treatment of cancer comprising cdc7 inhibitors |
| USPCT/US2019/019676 | 2019-02-26 | ||
| PCT/US2019/048657 WO2020068347A1 (en) | 2018-09-24 | 2019-08-28 | Methods of treatment of cancer comprising cdc7 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500479A JP2022500479A (ja) | 2022-01-04 |
| JP2022500479A5 true JP2022500479A5 (https=) | 2022-09-02 |
| JP7579781B2 JP7579781B2 (ja) | 2024-11-08 |
Family
ID=69952463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516638A Active JP7579781B2 (ja) | 2018-09-24 | 2019-08-28 | Ｃｄｃ７阻害剤を含む癌の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12533353B2 (https=) |
| EP (1) | EP3856352A4 (https=) |
| JP (1) | JP7579781B2 (https=) |
| KR (1) | KR20210064252A (https=) |
| CN (2) | CN121081469A (https=) |
| AU (1) | AU2019350581B2 (https=) |
| CA (1) | CA3113621A1 (https=) |
| WO (1) | WO2020068347A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019350581B2 (en) | 2018-09-24 | 2025-07-10 | Carna Biosciences, Inc. | Methods of treatment of cancer comprising Cdc7 inhibitors |
| MX2022000729A (es) * | 2019-07-19 | 2022-02-10 | Takeda Pharmaceuticals Co | Terapia de combinacion para el tratamiento del cancer. |
| EP4003994A4 (en) * | 2019-07-31 | 2023-09-13 | Oncour Pharma, Inc. | TREATMENT OF EVASIVE IMMUNE TUMORS |
| WO2022013328A1 (en) * | 2020-07-15 | 2022-01-20 | Université Libre de Bruxelles | Method for determining sensitivity to an antineoplastic agent |
| AU2024351866A1 (en) * | 2023-09-27 | 2026-04-09 | Carna Biosciences, Inc. | Novel combination therapy for blood cancer |
| CN117563005A (zh) * | 2023-10-26 | 2024-02-20 | 浙江大学 | 一种治疗结直肠癌的药物组合物及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JP2007501827A (ja) | 2003-08-08 | 2007-02-01 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なピリミジルピロール誘導体 |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| US7371862B2 (en) | 2005-11-11 | 2008-05-13 | Pfizer Italia S.R.L. | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| BRPI0709680B8 (pt) | 2006-03-27 | 2021-05-25 | Nerviano Medical Sciences Srl | derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase |
| AU2007240496A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of CDC7 |
| FR2907120B1 (fr) | 2006-10-12 | 2013-01-11 | Sanofi Aventis | Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7 |
| EP2118102B1 (en) | 2006-11-28 | 2013-06-12 | Nerviano Medical Sciences S.r.l. | Tricyclic indoles and (4,5-dihydro) indoles |
| ES2884044T3 (es) * | 2006-12-26 | 2021-12-10 | Immunogenesis Inc | Profármaco alquilante de fosforamidato para el tratamiento del cáncer |
| ES2546816T3 (es) | 2007-02-27 | 2015-09-28 | Nerviano Medical Sciences S.R.L. | Isoquinolinpirrolopiridinonas activas como inhibidores de cinasa |
| AR069869A1 (es) | 2007-12-21 | 2010-02-24 | Exelixis Inc | Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer. |
| WO2010101302A1 (en) | 2009-03-05 | 2010-09-10 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
| WO2010122979A1 (ja) | 2009-04-20 | 2010-10-28 | Ｓｂｉバイオテック株式会社 | チアゾリジノン誘導体 |
| CN102471339A (zh) | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡啶抑制剂 |
| ES2483594T3 (es) | 2009-07-15 | 2014-08-06 | Abbott Laboratories | Pirrolopirazinas inhibidoras de quinasas |
| AU2010319322A1 (en) | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| TW201127384A (en) | 2009-11-18 | 2011-08-16 | Nerviano Medical Sciences Srl | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent |
| SG183304A1 (en) | 2010-02-17 | 2012-09-27 | Takeda Pharmaceutical | Heterocyclic compound |
| AU2011224457B2 (en) | 2010-03-08 | 2014-11-06 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| US8450320B2 (en) | 2010-04-16 | 2013-05-28 | Abbvie Inc. | Pyrrolopyrazinone inhibitors of kinases |
| EP2558459B1 (en) | 2010-04-16 | 2014-01-22 | Abbvie Inc. | Phthalazin-(2h)-one inhibitors of kinases |
| CA2795422A1 (en) | 2010-04-19 | 2011-10-27 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
| US20120135989A1 (en) | 2010-06-29 | 2012-05-31 | Crystalgenomics, Inc. | Azaindole derivative |
| ES2687450T3 (es) | 2011-03-31 | 2018-10-25 | Carna Biosciences, Inc. | Nuevo derivado de furanona |
| JP6569908B2 (ja) | 2014-01-31 | 2019-09-04 | カルナバイオサイエンス株式会社 | 抗がん剤組成物 |
| CA3042849A1 (en) | 2016-11-04 | 2018-05-11 | Carna Biosciences, Inc. | Furanone derivates and methods of use thereof |
| WO2019165473A1 (en) * | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc | Methods of treatment of cancer comprising cdc7 inhibitors |
| AU2019350581B2 (en) | 2018-09-24 | 2025-07-10 | Carna Biosciences, Inc. | Methods of treatment of cancer comprising Cdc7 inhibitors |
-
2019
- 2019-08-28 AU AU2019350581A patent/AU2019350581B2/en active Active
- 2019-08-28 EP EP19866944.2A patent/EP3856352A4/en active Pending
- 2019-08-28 KR KR1020217010445A patent/KR20210064252A/ko not_active Ceased
- 2019-08-28 CN CN202511057693.2A patent/CN121081469A/zh active Pending
- 2019-08-28 CN CN201980069832.XA patent/CN113348020A/zh active Pending
- 2019-08-28 US US17/275,732 patent/US12533353B2/en active Active
- 2019-08-28 WO PCT/US2019/048657 patent/WO2020068347A1/en not_active Ceased
- 2019-08-28 JP JP2021516638A patent/JP7579781B2/ja active Active
- 2019-08-28 CA CA3113621A patent/CA3113621A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500479A5 (https=) | ||
| US20230398119A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| RU2589713C2 (ru) | Средство, усиливающее действие противоопухолевых средств | |
| JP2019532051A5 (https=) | ||
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| JP2021525768A5 (https=) | ||
| JP2017526698A5 (https=) | ||
| Bennouna et al. | Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study | |
| Younes et al. | Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results | |
| WO2018233620A1 (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
| JP2023024618A (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| Ali et al. | Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers | |
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| JP2016520665A (ja) | Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ | |
| CN111867678B (zh) | 治疗黑色素瘤的方法 | |
| JP2023505687A (ja) | 癌の処置方法 | |
| CN105611934A (zh) | 用于治疗化学敏感性或化学耐药性肿瘤的Dendrogenin A和抗肿瘤剂 | |
| CN110840892A (zh) | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途 | |
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023517671A5 (https=) | ||
| Xu | Progress in Therapy of Lung Cancer | |
| CN115243719A (zh) | CTB006与Ponatinib联合应用 | |
| CN106333951B (zh) | 一种mTOR激酶抑制剂与MAPK激酶抑制剂的组合物的应用 | |
| CN107137403B (zh) | 一种pi3k/mtor抑制剂在制备治疗胰腺癌的药物中的用途 |